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Abstract
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder 
associated with dementia as a main feature. Despite decades of thorough 
research in the field of AD, the pathomechanism is still not fully 
understood. The development of novel experimental models can help us 
in the discovery of both genetic and non-genetic components of disease 
pathogenesis. As currently available therapies in AD can provide merely 
moderate or only temporary symptomatic relief, there is a great demand 
for the development of new drugs with higher therapeutic potential. 
Some of the candidates would be those of targeting the kynurenine 
pathway, the neuroactive metabolites of which are surely involved in 
both neurodegeneration and neuroprotection, mainly in relation with 
glutamate excitotoxicity and oxidative stress. Both analogs of the 
neuroprotective kynurenic acid and small molecule enzyme inhibitors 
preventing the formation of neurotoxic compounds may have potential 
therapeutic significance. However, there is a great need for new 
strategies via which to improve the efficacy, the transport across the 
blood-brain barrier and bioavailability, naturally with simultaneous 
minimization of the adverse side-effects.
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Alzheimer’s disease
Alzheimer’s disease (AD) is the most common age-related, progressive 
neurodegenerative disorder. It usually starts with a memory loss and 
leads to a cognitive deficit and dementia. There are many behavioral 
symptoms, e.g. aggression, agitation and psychosis, which are 
responsible for the distressing aspect of AD and pose a great emotional, 
physical and economic challenge [1-2]. AD selectively affects numerous 
neuronal populations involving glutamatergic neurons in the 
hippocampus and cortex, basal forebrain cholinergic neurons and 
brainstem monoaminergic neurons [3-5] and cortical synapses [6-7]. The 
disease is characterized by neuropathological changes such as amyloid-
beta (Aβ) plaques and neurofibrillary tangles, in the regions responsible 
for memory formation consisting of glutamatergic circuits. A severe 
reduction in mitochondrial complex IV activity suggests that an energy 
deficit plays a key role in the development of AD [8]. Most AD cases are
sporadic and numerous heritable mutations in the amyloid-β precursor 
protein (AβPP), which belongs to the type 1 transmembrane family of 
glycoproteins, have been linked to the disease. The AβPP has a Swedish 
mutation, in which Lys-595 and Met-596 are replaced by Asp and Lys, 
respectively. This enhances the early onset and propagation of AD, and 
leads to the cognitive impairments associated with AD [9]. The 
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expression of the Swedish mutation alters the overall gene expression, 
including AD-related kinases, phosphatases, presenilin-2, and glycogen 
synthase kinase-3β [10]. The cleavage of AβPP by β- and γ-secretases 
leads to the formation of Aβ peptides, which assemble into extracellular 
amyloid plaques [11]. Close correlations were reported in earlier studies 
between the severity of the different diseases and the degree of amyloid 
accumulation. It has recently become rather uncertain whether amyloid 
aggregates really are the basic toxic species amongst conformational 
forms. These may rather represent a protective mechanism by 
segregation of toxic intermediates in the amyloid assembly pathway [12].
Presenilin-1 is the most common gene in AD and 177 mutations have so 
far been identified in this gene. One of the up-to-date mutations in 
presenilin-1, I202F, occurs in exon 7 of the presenilin-1 gene and the 
fourth transmembrane domain of presenilin-1 protein. This new mutation
fits the pattern, in accordance with previously defined presenilin-1 
mutations, lining up along the helical transmembrane domains of 
presenilin-1 [13-14].
Insoluble fibrillar tau-protein deposits are typically observed within the 
cell bodies and dendrites of the neurons [15]. These neurofibrillary 
tangles are the other major pathogenic marker of AD. R406W is the 
unique tau mutation causing AD-like dementia and tauopathy in humans 
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and it has the special ability to reduce tau phosphorylation in cultured 
cells [16-18] or in vitro by recombinant glycogen synthase kinase-3β 
[19].
Some in vivo models of Alzheimer’s disease
The most important task at present is to develop new disease-modifying 
modes of treatment. Before making effort to stop or at least slow 
neurodegenerative processes, a better understanding of the 
pathophysiology of diseases is needed, which demands on better animal 
models. With the aid of such animal models, new disease-modifying 
therapies can be tested and improved. The ideal animal model should 
meet many requirements. However, it must be borne in mind that animal 
models can never be perfect. Certain biochemical and physical 
differences have been demonstrated in the amyloid plaques in AD 
patients and in AD animal models. In one of the transgenic mouse 
models of AD, the ATP-gated P2X7 purinergic receptor cation channel is
upregulated around amyloid peptide plaques and co-localizes to 
microglia and astrocytes. After ischemia in the cerebral cortex of rats and
also following spinal cord injury, upregulation of the P2X7 receptor 
subtype on the microglia occurs, while the P2X7 receptor-like 
immunoreactivity is enhanced in the activated microglial cells of the MS 
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and ALS spinal cord [20]. As an in vitro model for neuroinflammation 
involving the application of neuron/microglia co-cultures, P2X7 receptor 
activation on microglia appears necessary for the microglial cell-
mediated injury of neurons.
In recent years, a novel triple mutant mouse model of AD (3xTgAD 
mice) has been generated, in which the mice exhibit age-dependent Aβ 
deposition and tau-pathology in the hippocampus and cerebral cortex 
[21-22]. These mice express familial AD AβPP and presenilin-1 
mutations, together with a tau mutation [21].
Non-mammalian organisms can also provide suitable information about 
the disease. In a nematode, a Caenorhabditis elegans screening mutation 
revealed a relationship between presenilins and the Notch signaling 
pathway [23]. In consequence of human Aβ expression in 
Caenorhabditis elegans [24] and Drosophila melanogaster [25], amyloid
deposits in muscle and neurodegeneration can also be observed. With the
help of yeast, Aβ toxicity can be studied well [26]. As a brief evasive as 
regards the use of yeast in modelling neurodegenerative disorders, it is 
important to mention here that Giorgini et al performed a genomic screen
in yeast to identify gene deletions that suppress the toxicity of a mutant 
Htt fragment (Htt103Q). This study suggests that a conserved mechanism
of polyQ toxicity might be observed in yeast and Huntington’s disease 
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(HD) patients involving upregulation of the kynurenine pathway 
metabolites. The mitochondrial kynurenine 3-monooxygenase is 
activated in HD patients and also in animal model of HD. 
Pharmacological inhibition of this may revise mutant Htt-mediated 
toxicity [27]. Later they published that a histone deacetylase (HDAC) 
inhibitor entirely blocks increases in kynurenine pathway metabolites in 
microglia of HD mice. This suggests that transcription of the kynurenine 
pathway is regulated by HDAC activity in mammalian cells [28]. So the 
yeast genom screening might serve as a rapid testing tool to explore the 
involvement of kynurenine pathway alterations in the development of 
AD. Use of these organisms has provided a possibility for the screening 
of drug libraries with the aim of the discovery of new compounds that 
block Aβ toxicity [29]. Paquet et al. have created the transgenic 
expression of the human tau-P301L protein in zebrafish neurons, in a 
design involving a Gal4-upstream activating sequence-based vector 
system [30]. The pathology of the disease, the specific 
hyperphosphorylation and the conformational changes in tau, can be 
better monitored than earlier. This is the first demonstration of in vivo 
cell death imaging. Additionally, neurons can be observed in their natural
environment, together with astroglia, oligodendrocytes and microglia 
[31]. Because of the rapid appearance of pathologic phenotypes, 
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transgenic zebrafish larvae can be utilized not only to monitor and 
understand processes of diseases in vivo, but also to test and validate 
drugs on a large scale [30] (Table 1).
Mitochondrial impairment and neurodegeneration
The key cytoplasmic organelles, the mitochondria, are vital for the 
function and survival of neurons. These are the energy powerhouse of the
cells, because they provide energy from the aerobic metabolism.
Mitochondria are both important sources and targets of reactive oxygen 
species (ROS). Damaged mitochondria demonstrate an increased level of
generation of reactive oxidants, e.g. ROS. Healthy aging is associated 
with a decreased neuronal mitochondrial metabolism and recent studies 
suggested an altered glial mitochondrial metabolism [32]. High levels of 
ROS can induce mitochondria-impairing mechanisms, such as a 
mitochondrial permeability transition, and uncouple oxidative 
phosphorylation, leading eventually to cell death via apoptosis or 
necrosis. The mitochondrial damage can comprise a respiratory chain 
enzyme or mitochondrial DNA (mtDNA) impairment. Oxidative stress 
and damaged mtDNA in aging impair the ion homeostasis and 
mitochondrial energy metabolism in the neurons, thereby making them 
vulnerable to degeneration [33]. Dysfunctions of the mitochondrial 
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energy metabolism contribute to the generation of ROS, disturbed Ca2+ 
buffering and a reduced ATP metabolism [34].
In the AD brain, the significantly enhanced oxidative damage may cause 
a mitochondrial dysfunction and abnormal dynamics, leading to an 
energy deficit in AD neurons [35]. The oligomeric Aβ peptide plays a 
crucial role in the formation of the mitochondrial permeability transition 
pore [36], thereby contributing to the mitochondrial dysfunction in the 
AD brain [37], including impaired ATP production and increased levels 
of oxidative stress. Impaired axonal transport with the proximal 
accumulation of mitochondria can lead to the loss of distal synapses [38].
Altered calcium homeostasis has also been reported in AD, related to Aβ 
production, presenilin mutations and tau phosphorylation [39-40].
The role of excitotoxins in neurodegeneration
One of the major causes of the development of neurodegenerative 
processes is excitotoxicity, first described by Olney in 1969 [41]. During 
this pathological phenomenon, neurons are damaged or killed by the 
overactivation of receptors of excitatory neurotransmitters, such as N-
methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA)/kainate receptors. Classical 
excitotoxicity involves three connected steps of a cascade mechanism 
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that occur in parallel: a Na+ influx, a Ca2+ influx and the exocytosis of 
glutamic acid, leading to persistent depolarization of the neurons. 
Glutamate is the major excitatory neurotransmitter in the mammalian 
CNS, and the principal example of an excitotoxin in the brain [42]. The 
abnormal function of glutamate receptors may result in an enhanced 
release of glutamate. The changes in glutamate uptake may elevate the 
extracellular concentration of glutamate accompanying the excitotoxic 
process [43]. Excitotoxicity can occur in consequence of endogenous 
excitotoxins. These substances, which can act on the receptors of cerebral
excitatory amino acids, may also play important roles in the pathogenesis
of certain brain disorders, e.g. AD, Parkinson’s disease, HD, amyotrophic
lateral sclerosis, stroke, multiple sclerosis (MS), epilepsy and migraine 
[44-45]. The activation of excitatory amino acid receptors results in the 
selective neuronal death characteristic of these diseases [46-48]. In the 
pathogenesis of AD, glutamate excitotoxicity plays a key role. Neurons 
exposed to Aβ demonstrate increased vulnerability to this phenomenon. 
Overstimulation of ion-channel glutamate receptors may result in 
oxidative events and these receptors are up-regulated following Aβ 
exposure. The glutamatergic tone and Aβ may act synergistically [49]. 
Some studies suggest that in specific brain areas glutamatergic signaling 
is compromised by Aβ-induced modulation of synaptic glutamate 
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receptors, resulting in an early cognitive deficit [50]. A Ca2+ overload can
raise the level of kinase activation, with the formation of neurofibrillary 
tangles [51].
Drugs that block NMDA or other glutamate receptors, and also 
compounds that decrease glutamate release, attenuate some of the 
pathological symptoms in experimental models of acute and chronic 
neurodegenerative diseases [52]. As NMDA receptor antagonists, the 
glycine and polyamine site agents, NR2B subunit specific antagonists 
and ion channel blockers may come into consideration as they have 
acceptable side-effects [53]. Thus, the glycine site agent kynurenic acid 
(KYNA) might appear to be a good candidate, but from a 
pharmacological aspect, it has several disadvantages, mainly as regards 
the route of its administration, its elimination half-life and its penetration 
through the blood-brain barrier. In recent years, therefore, several new 
KYNA analogs or prodrugs have been designed in attempts to get round 
these disadvantages [54]. One of the most important groups of these 
compounds comprises the KYNA amides [55], which may selectively 
inhibit the NR2B subunit of NMDA receptors [56].
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Summary of currently available therapies in Alzheimer’s disease
Cholinesterase inhibitors can moderate AD. Through impeding of the 
action of acetylcholinesterase (AChE) with AChE inhibitors (AChEIs), 
the action of ACh and its interaction with cholinergic receptors and K+ 
channels can be prolonged. AChEIs such as donepezil, rivastigmine and 
galantamine have moderate beneficial effects on memory and cognition 
[57]. In vitro studies have revealed that donepezil possesses a 
neuroprotective effect through decreasing glutamate excitotoxicity, 
reducing Aβ toxicity and increasing the survival of cells. In contrast, 
donepezil and rivastigmine offer only a symptomatic effect without 
neuroprotection [58-59]. 
An AChEI of natural origin, galantamine, provides protection for neurons
and reduces cell death. Galantamine can increase dopaminergic 
neurotransmission in the hippocampus of mice [60]. In the human brain, 
galantamine either prevents or improves the decline of cognition and 
daily activities [61].
As compared with donepezil and galantamine, rivastigmine is more 
effective because it can inhibit both AChE and butyrylcholinesterase. It 
can reduce the cortical atrophy and slow the rate of decline for as long as 
5 years [62-63].
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Memantine is an NMDA receptor antagonist [64] which inhibits the 
influx of Ca2+, thereby reducing cell damage and resulting in moderate 
improvements in behavior and cognition [65]. This is the only well-
tolerated and safe drug in clinical use for AD that targets the 
glutamatergic system. There are reports that memantine can inhibit the 
abnormal phosphorylation of tau [66-67]. A comparative study has 
indicated that neither donepezil nor memantine furnishes a significant 
improvement in mild AD [68].
The kynurenine pathway and its alterations in Alzheimer’s disease
L-Kynurenine (L-KYN) is one of the major intermediates of the 
tryptophan metabolism, in which L-tryptophan is transformed into 
nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine 
dinucleotide phosphate, these two co-enzymes being essential for cellular
mechanisms [54; 69-70] (Figure 1). L-KYN, the central compound of the
kynurenine pathway, can be metabolized in two distinct pathways, to 
KYNA or to 3-hydroxy-L-kynurenine (3-OH-L-KYN) and quinolinic 
acid (QUIN). Under both physiological and pathological conditions, 
these neuroactive kynurenines play pivotal roles [71] (Table 2).
60% of the mammalian brain L-KYN content is taken up from the blood 
by a neutral amino acid carrier, and the remaining 40% is produced 
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locally in the brain [72]. The rate of cerebral L-KYN production has been
reported to be 0.29 nmol/g/h [73]. Its key role is to serve as a precursor of
neuroprotective KYNA and the neurotoxic 3-OH-L-KYN (Figure 2). The
level of L-KYN in the cerebrospinal fluid (CSF) does not change in AD. 
L-KYN is transformed to KYNA by irreversible transamination on the 
action of kynurenine aminotransferases (KATs). In high, 
nonphysiological concentrations, KYNA has proved to be a broad-
spectrum endogenous antagonist of ionotropic excitatory amino acid 
receptors [74]. It exhibits a high affinity for the glycine-binding site of 
the NMDA receptor, blocking its activity in low micromolar 
concentrations [75] and it is additionally a weak antagonist of the 
AMPA/kainate receptors [76]. It has recently been demonstrated that 
KYNA in nanomolar concentrations displays a neuromodulatory effect, 
whereas in micromolar concentrations, above the physiological range, it 
inhibits the neuronal activity [77-78]. Moreover, KYNA 
noncompetitively blocks the α7-nicotinic acetylcholine (α7-nACh) 
receptors and can increase the expression of non-α7-nACh receptors [79-
80]. It has been concluded that cross-talk occurs between KYNA and the 
cholinergic system, a situation which has been presumed to play a role in 
the pathogenesis of numerous brain impairments [81]. In view of its 
pharmacological activity, it seems to possess a neuroprotective potential, 
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but in very high concentrations it can exert adverse effects, as 
exemplified by the intracerebroventricular injection of KYNA into rats, 
which results in reduced exploratory activity, ataxia, stereotypy, sleeping 
and respiratory depression [82]. Under physiological conditions, 
elevation in KYNA concentration can result in cognitive impairment [83-
84]. However, under pathological conditions, the situation can be 
different. Due to glutamate excitotoxicity, a receptor overactivation 
occurs, where anti-glutamatergic agents can help in setting up again the 
basal level of activation, promoting a memory regain in cognitive 
impairment.
QUIN participates in the kynurenine pathway, leading to the synthesis of 
the essential co-enzyme NAD+. It is present in nanomolar concentrations 
in the brain and exerts pronounced effects on the NMDA-sensitive 
subpopulation of glutamate receptors [85]. It is a weak, but specific 
competitive agonist of the NR2A and NR2B NMDA receptor subtypes 
[86-87]. When the level of QUIN in the brain becomes elevated, it 
exhibits an excitatory effect at the NMDA receptors. It can provoke lipid 
peroxidation [88], produce toxic free radicals [89] and induce astrocytes 
to generate various chemokines, such as IFN-γ, IL-1β and TNF-α [90-
92]. Interesting results are manifested by AD patients as concerns the 
immunoreactivity of QUIN and one of the first tryptophan metabolism 
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enzymes, indoleamine-2,3-dioxygenase-1 (IDO-1). High expressions of 
QUIN and IDO-1 have been observed in the human hippocampus and 
neocortex and in senile plaques [93]. In the hippocampus of the AD 
brain, which is one of the most vulnerable regions in AD, both IDO-1 
expression and QUIN accumulation have been detected in the cortical 
microglia, astrocytes and neurons [93]. IDO is induced in various types 
of inﬂammation, and complex and multiple inﬂammation occurs in AD 
progression [94]. The observed up-regulation of IDO and the 
accumulation of QUIN are thus considered to be feasible. It has been 
shown that a soluble oligomer of Aβ peptide activates the microglia in 
vitro, while inducing QUIN production and IDO expression in the cells 
[95]. Stone et al. reported that free radicals may be involved in the 
neurotoxic effects of QUIN and considered the possibility that QUIN 
may play a role in AD [96].
3-OH-L-KYN may also cause neuronal death because it generates ROS 
[97]. Bonda et al. used immunocytochemical methods to demonstrate the 
roles of some intermediates of the kynurenine pathway in the 
pathogenesis of AD. They observed that 3-OH-L-KYN and its cleaved 
product 3-hydroxyanthranilic acid (3-HAA) significantly damage the 
neuronal tissues and presumably participate in neurodegeneration 
through glial activation, consequent Aβ activation and upregulation of 
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the kynurenine pathway. Elevated levels of 3-OH-L-KYN and the rate-
limiting enzyme IDO-1 were observed; this latter was shown to be 
specifically localized in conjunction with neurofibrillary tangles, and the 
association of IDO-1 with senile plaques was confirmed [98].
Pharmacological manipulation of the kynurenine pathway with a 
view to the treatment of Alzheimer’s disease
Abnormalities of the kynurenine pathway clearly play a crucial role in 
the neurodegeneration involved in various neurological and psychiatric 
disorders [71]. Subsequent to the availability of novel pharmacological 
agents, a number of interesting features of L-KYN biology have recently 
been discovered [54]. In another animal model, L-KYN combined with 
probenecid rescued the Schaffer collateral-CA1 synapses from impaired 
long-term potentiation induction after transient global ischemia [99].
One of the most important treatment possibilities is the modulation of 
kynurenergic compounds because this can furnish one of the greatest 
biochemical armaments [100]. Effective inhibitors of mammalian 
kynurenine 3-hydroxylase, 4-chloro-3-hydroxyanthranilic acid (4-Cl-3-
HAA) oxygenase and IDO have been available for years. The targeting 
of other pathway enzymes has lagged behind. Most of the original 
enzyme inhibitors were simple derivatives or structural analogs of the 
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naturally occurring substrates, e.g. for 3-HANA oxygenase and 1-
methyltryptophan (for IDO).
With regard to the pharmacological features of the kynurenines, an 
elevated level of KYNA in the CNS seems to be a potential therapeutic 
possibility. Fortunately, KYNA behaves as an endogenous 
neuroprotective agent and can prevent neuronal loss following 
excitotoxic, infectious or ischemia-induced neuronal injuries [101-103].
5,7-Dichlorokynurenic acid and 7-chlorokynurenic acid (7-Cl-KYNA) 
are well-known KYNA analog NMDA glycine site antagonists [104]. 
5,7-Dichlorokynurenic acid did not reverse the phosphatase inhibitor 
okaidic acid-induced AD-type abnormal hyperphosphorylation of tau in 
hippocampal organotypic cultures [105]. The in situ production of 7-Cl-
KYNA can be achieved through use of the blood-brain penetrable pro-
drug 4-chlorokynurenine (4-Cl-KYN), which is preferentially 
metabolized in brain areas where neurodegeneration takes place, 
allowing administration of a lower dosage of the drug [106]. The 
systemic administration of 4-Cl-KYN did prevent quinolinate-induced 
neurotoxicity in the hippocampus of the rat [107]. Further, 4-Cl-KYN 
can be transformed into 4-Cl-3-HAA, a potent, selective inhibitor of 3-
HAA oxygenase [108], and thus it can inhibit QUIN synthesis too, 
besides blocking the NMDA receptors. Hence, modification of the 
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kynurenine pathway through pharmacological inhibition of the enzymes 
of QUIN synthesis is a rational approach via which to divert the 
kynurenine metabolism toward the neuroprotective KYNA [109].
Novel chemical structures have been identified by further rational design 
or by screening chemical libraries (e.g. the discovery of N-(4-
phenylthiazol-2-yl)benzenesulfonamides as potent kynurenine 3-
hydroxylase inhibitors) [110]. Potent and speciﬁc kynureninase blockers 
which preferentially inhibit the mammalian enzyme were recently 
synthesized [111-112]. These enzyme inhibitors have so far not been 
examined in vivo, but can be expected to play a crucial part in the 
dynamics of the kynurenine pathway metabolism [54].
Conclusion
The search for effective treatments for neurodegenerative disorders 
[113], especially for AD, is currently one of the most important topics of 
research relating to healthcare. Drug screening can be carried out through
the use of different animal models and new biochemical targets. 
Following reassuring preclinical results, the design of clinical studies 
might be considered. The pharmacological manipulation of the 
kynurenine pathway, either using analogs of the pathway compounds or 
small molecule enzyme inhibitors would serve as promiseful therapeutic 
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approaches. However, the synthetic compounds should match several 
criteria. For example, prolonged absorption into the circulation, increased
plasma half-life, better penetration through the blood-brain barrier and 
rather selective pharmacodynamic actions should be aimed at. 
Furthermore, the designed compounds should have as few side-effects as 
possible at the protective dose. In relation to AD, none of the drugs, 
targeting the kynurenine pathway, has ever been tested in clinical trials. 
Although there are numerous reassuring preclinical experiments, it is 
hard to set up well-designed clinical trials for several reasons. Firstly, it 
would be hard to carry out the testing of kynurenine pathway targeting 
compounds, especially the KYNA analogues, in normal subjects, because
under normal conditions, these may induce cognitive dysfunction. 
Secondly, it would be to risky to test these compounds alone in patients 
with AD, lacking the currently used therapeutic agents. However, the set 
up of well-designed treatment regimes, using promising kynurenine 
pathway targeting compounds as a part of combination therapies with 
currently available therapeutic agents in AD may exert additional 
beneficial effects in that devastating disease. Hopefully, drugs targeting 
the kynurenine pathway would serve as an alternate choice amongst anti-
glutamatergic agents in addition to the currently available memantine in 
the future treatment of AD.
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Figure 1.
A schematic outline of the kynurenine pathway  
The kynurenine pathway is involved in the metabolism of tryptophan, in 
which L-tryptophan is transformed into NAD+ and neuroactive 
intermediates, such as KYNA and QUIN.
Figure 2.
The role of kynurenine pathway in the neuronal function 
L-TRP: L-tryptophan; L-KYN: L-kynurenine; 3-OH-L-KYN: 3- 
hydroxy-L-kynurenine; KYNA: kynurenic acid; 3-HAA: 3-
hydroxyanthranilic acid; QUIN, quinolinic acid; NMDA-R: NMDA 
receptor; α7-nACh-R, α7 nicotinic acetylcholine receptor
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Disease  Model  Results  References
Alzheimer's disease
 transgenic AD mice, rats  P2X7 receptor antagonist improvesrecovery after spinal cord injury  [20]
3xTgAD mice preserved learning and memory [21-22]
human presenilin-1 mutant C.
elegans
relationship between presenilins and
Notch signalling [23]   
human Aβ expression in tg C.
elegans
in vivo investigation of factors that
modulate amyloid formation [24]   
Drosophila model of AD reduction of Aβ aggregation [25]   
Aβ in yeast fibrillar Aβ has low toxicity [26]   
 human tau-P301L protein inzebrafish  
hyperphosphorylation can be
monitored well  [30]   
Table 1. Some in vivo models of Alzheimer’s disease
AD: Alzheimer’s disease; Aβ: amyloid-beta; C. elegans: Caenorhabditis elegans
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Metabolite Level Function Dysfunction Reference
L-KYN Normal precursor of 
KYNA and 3-OH-
L-KYN
[73-74]
KYNA High
Low
it has proved to be 
a broad spectrum 
endogenous 
antagonist of 
ionotropic EAARs
it has 
neuromodulatory 
effect;
non-competitively 
blocks the α7-
nACh receptors 
and increases the 
expression of it
it inhibits 
physiological 
neuronal activity
[74]
[77-78]
[77]
[79-81]
QUIN Normal
high
It is a specific 
agonist of NMDA 
receptor subtypes
it can provoke 
lipid peroxidation, 
produce toxic free 
radicals and induce
astrocytes to 
[86-87]
[88-92]
42
generate 
chemokines
3-OH-L-KYN Normal
high
causes neuronal 
death
damages neuronal 
tissues, 
participates in 
neurodegeneration 
through glial 
activation and Aβ 
activation
[97]
[98]
Table 2.
Biochemical implications of kynurenine metabolites in neuronal function
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